Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059958 | 0.95 | NOS1 (0.48) | NOS1NOS2CHRM5CYP1A2ADRA2C | |
| SCHEMBL3637082 | 0.93 | NOS1 (0.41) | NOS1NOS2 | |
| SCHEMBL3636427 | 0.79 | CYP1A2 (0.38) | NOS1NOS2CYP1A2 | |
| SCHEMBL1516342 | 0.73 | NOS1 (0.38) | NOS1NOS2 | |
| SCHEMBL9679332 | 0.70 | ADH1B (0.41) | NOS1NOS2CHRM5CHRM2CHRM4 | |
| SCHEMBL23070439 | 0.69 | CHRM5 (0.43) | NOS1NOS2CHRM5CYP1A2ADRA2C | |
| SCHEMBL187659 | 0.69 | CHRM5 (0.43) | NOS1NOS2CHRM5CYP1A2ADRA2C | |
| SCHEMBL11006113 | 0.69 | CHRM5 (0.43) | NOS1NOS2CHRM5CYP1A2ADRA2C | |
| SCHEMBL6532715 | 0.69 | CHRM5 (0.43) | NOS1NOS2CHRM5CYP1A2ADRA2C | |
| SCHEMBL1524658 | 0.69 | CHRM5 (0.43) | NOS1NOS2CHRM5CYP1A2ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507753-B2 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1466904-A1 | BIARYL COMPOUND AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-6515025-B2 | Renin inhibitor | PHARMACIA CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-20020025934-A1 | Ethynyl alanine amino diol compounds for treatment of hypertension | G.D. SEARLE & CO. (US) | 2002-02-28 | — | — | US | disclosed |
| US-6281235-B1 | CONTROL OF HYPERTENSION. | G.D. SEARLE & CO. | 2001-08-28 | — | — | US | disclosed |
| US-6174923-B1 | ADMINISTERING ETHYNYL ALANINE AMINO DIOL COMPOUND FOR TREATING HYPERTENSION | G. D. SEARLE & CO. | 2001-01-16 | — | — | US | disclosed |
| US-5942548-A | ACT AS RENIN INHIBITORS; ADMINISTERING TO TREAT CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1999-08-24 | — | — | US | disclosed |
| US-5849773-A | Amino acyl amino propargyl diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5508295-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5484811-A | ADMINISTERING A RENIN INHIBITOR TO A SUBJECT | G. D. SEARLE & CO. (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0610451-A1 | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5330996-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1994-07-19 | — | — | US | disclosed |
| US-5227401-A | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G. D. SEARLE & CO. (US) | 1993-07-13 | — | — | US | disclosed |
| WO-1993009108-A1 | AMINO ACYL AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1993009087-A1 | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0539976-A1 | Ethynyl-alanine-amino-diol compounds for treatment of hypertension | G.D. Searle & Co. (US) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | MC4R, MC3R, MC1R | NOS1 1962/4885NOS2 1559/4885CHRM5 401/4885 |
| US-20020025934-A1 | Ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGTR1, AGT | NOS1 229/4885NOS2 232/4885CHRM5 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.